Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT00140075
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Colorado Springs, Colorado
Conditions: Adenocarcinoma
Register for Updates
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NCT00002707
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado +1 locations
Conditions: Breast Cancer
Register for Updates
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
NCT00016458
Completed
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin in patients with diffuse systemic sclerosis. II. Determine the efficacy of this regimen in terms of controlling disease in these patients.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
09/02/2008
Locations: University of Colorado Cancer Center, Denver, Colorado
Conditions: Systemic Sclerosis
Register for Updates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00131313
Unknown
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2005
Locations: The Oncology Clinic, PC, Colorado Springs, Colorado +1 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
NCT00014755
Completed
OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this regimen. III. Determine the safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/23/2005
Locations: University of Colorado Cancer Center, Denver, Colorado
Conditions: Multiple Sclerosis
Register for Updates